Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.05

€1.05

-
-
-
€1.60
 
29.02.24 / Frankfurt WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cerenis Therapeutics Holding S.A. Stock

The community is currently still undecided about Cerenis Therapeutics Holding S.A. with 1 Buy predictions and 0 Sell predictions.
However, we have a potential of -4.76% for Cerenis Therapeutics Holding S.A. as the target price of 1 € is below the current price of 1.05 €.
For the coming years our community has positive and negative things to say abot the Cerenis Therapeutics Holding S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years

Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cerenis Therapeutics Holding S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cerenis Therapeutics Holding S.A. - -0.756% -10.866% -41.860% -14.773% 23.384% 138.636%
Sensorion SA 6.420% 5.364% 64.016% 154.237% 106.250% -60.526% -
Genoway S.A. Inh. -1.310% -3.046% -7.056% 2.965% -13.379% 5.234% 57.202%
Hybrigenics S.A. -3.370% -44.375% -25.833% -85.895% -52.910% -97.595% -93.154%

News

ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112


Access here the full press release



ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies

ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D


ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant

ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week": https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"


ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant